...
首页> 外文期刊>Protein & Cell >CRISPR/Cas9-mediated targeted gene correction in amyotrophic lateral sclerosis patient iPSCs
【24h】

CRISPR/Cas9-mediated targeted gene correction in amyotrophic lateral sclerosis patient iPSCs

机译:CRISPR / Cas9介导的肌萎缩性侧索硬化患者iPSC的靶向基因校正

获取原文

摘要

Amyotrophic lateral sclerosis (ALS) is a complex neurodegenerative disease with cellular and molecular mechanisms yet to be fully described. Mutations in a number of genes including SOD1 and FUS are associated with familial ALS. Here we report the generation of induced pluripotent stem cells (iPSCs) from fibroblasts of familial ALS patients bearing SOD1 +/ A272C and FUS +/ G1566A mutations, respectively. We further generated gene corrected ALS iPSCs using CRISPR/Cas9 system. Genome-wide RNA sequencing (RNA-seq) analysis of motor neurons derived from SOD1 +/ A272C and corrected iPSCs revealed 899 aberrant transcripts. Our work may shed light on discovery of early biomarkers and pathways dysregulated in ALS, as well as provide a basis for novel therapeutic strategies to treat ALS.
机译:肌萎缩性侧索硬化症(ALS)是一种复杂的神经退行性疾病,其细胞和分子机制尚待充分描述。包括SOD1和FUS在内的许多基因的突变都与家族性ALS相关。在这里,我们报告了分别由携带SOD1 + / A272C 和FUS + / G1566A 的家族性ALS患者的成纤维细胞诱导多能干细胞(iPSC)的产生。我们进一步使用CRISPR / Cas9系统生成了基因校正的ALS iPSC。来自SOD1 + / A272C 和校正后的iPSC的运动神经元的全基因组RNA测序(RNA-seq)分析显示了899个异常转录本。我们的工作可能会揭示ALS中失调的早期生物标志物和途径的发现,并为治疗ALS的新型治疗策略提供基础。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号